MIRA
MIRA Pharmaceuticals, Inc. NASDAQ Listed Aug 14, 2023$1.01
+11.27%
vs $0.91
Mkt Cap $23.9M
52w Low $0.91
9.2% of range
52w High $2.02
50d MA $1.01
200d MA $1.26
P/E (TTM)
—
EV/EBITDA
—
P/B
2.3x
Debt/Equity
0.0x
ROE
-100.5%
P/FCF
-5.1x
RSI (14)
51.70
ATR (14)
$0.04
Beta
1.94
50d MA
$1.01
200d MA
$1.26
Avg Volume
125.1K
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.
CIK (SEC)
Phone
737-289-0835
855 North Wolfe Street · Baltimore, MD 21205 · US
Data updated apr 26, 2026 12:21pm
· Source: financialmodelingprep.com